Uni-Bio Science Group Limited (Uni-Bio) announced that all eight resolutions proposed at its Annual General Meeting on 26 May 2026 were approved by poll, underscoring broad shareholder support for the company’s strategic and governance agenda.

The meeting was attended in person, by corporate representatives or by proxy, with 5.97 billion shares—representing 100% of Uni-Bio’s issued share capital—entitled to vote. Tricor Investor Services Limited acted as the independent scrutineer.

Key voting outcomes:

• Financial Statements and Reports: The audited consolidated financial statements for the year ended 31 December 2025, along with the directors’ and auditors’ reports, were adopted with 100.00% of votes in favour (819.23 million shares).

• Board Composition: Re-election of Mr. Chen Dawei, Mr. Zhao Zhi Gang and Mr. Yau Kwok Wing Tony each received 98.70% support (808.57 million shares). Director remuneration authority was backed by 99.90% of votes.

• Auditor Renewal: BDO Limited was re-appointed as external auditor with 94.44% approval (773.67 million shares).

• Capital Authorisations: – General Mandate to issue new shares passed with 93.76% support (768.09 million shares). – Repurchase Mandate allowing buy-backs of the company’s shares secured unanimous approval at 100.00% (819.23 million shares). – Extension of the issue mandate to include repurchased shares also passed with 93.76% support.

• Corporate Governance: Shareholders endorsed the adoption of the Second Amended and Restated Articles of Association with 100.00% approval.

• Dividend: A final dividend of HK0.313 cents per share, to be paid out of the share premium account, was approved with unanimous consent.

All directors—comprising Executive Directors Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief Executive) and Dr. Wen Yalei (Chief Operating Officer); Non-executive Directors Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and Independent Non-executive Directors Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan—were present at the meeting.

The comprehensive shareholder endorsement provides the Board with a strengthened mandate to execute its strategic initiatives, capital management plans and corporate governance enhancements in the coming year.